 |
|
|
|
|
Indiana Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing IndianaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Endocyte, Inc.
| | | | | Phone: | (765) 463-7175 | | Fax: | (765) 463-9271 | | Year Established: | 1996 | | Ticker: | NVS | | Exchange: | NYSE | | Main Contact: | Matthew Call, VP, Business Development | | | | Other Contacts: | Alison A. Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR, CMO
Iontcho Vlahov Ph.D, VP, Discovery Chemistry
Christopher Leamon, Ph.D., VP, R&D
Philip Low, Ph.D., CSO
Michael T. Andriole, CFO
Mike Sherman, President & CEO
| | | | Company Description | | Endocyte, a Novartis company, is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. | |
|
|
|
|
|
|
|
